NR reports commercial associations with GlaxoSmithKline, Abbott Laboratories, Pfizer, Inc., and Janssen. MK reports commercial associations with Bristol-Myers Squibb, Collegium, Cypress Bioscience, Cyberonics, Eli Lilly & Co., Forest Laboratories, Janssen, Merck, Inc., Organon, Otsuka, Pfizer, Inc., Pharmastar, Sepracor, Vela Pharmaceuticals, Wyeth, Abbott Laboratories, Cephalon, Inc., GlaxoSmithKline, Mitsubishi Pharma Corp., Somerset Pharmaceuticals, Scirex and Sanofi-Synthelab. MS, BB, DA, SV, HL, SI, MKG and JH have no reported conflict of interest.
Pediatric bipolar disease: current and future perspectives for study of its long-term course and treatment
Article first published online: 18 JUL 2006
Volume 8, Issue 4, pages 311–321, August 2006
How to Cite
Strober, M., Birmaher, B., Ryan, N., Axelson, D., Valeri, S., Leonard, H., Iyengar, S., Gill, M. K., Hunt, J. and Keller, M. (2006), Pediatric bipolar disease: current and future perspectives for study of its long-term course and treatment. Bipolar Disorders, 8: 311–321. doi: 10.1111/j.1399-5618.2006.00313.x
- Issue published online: 18 JUL 2006
- Article first published online: 18 JUL 2006
- Received 7 January 2005, revised and accepted for publication 13 September 2005
- bipolar illness;
- early onset;
Aim and methods: Findings from recent long-term, prospective longitudinal studies of the course, outcome and naturalistic treatment of adults with bipolar illness are highlighted as background for long-term developmental study of pediatric bipolar illness.
Results: Accumulating knowledge of bipolar illness in adults underscores a high risk for multiple recurrences through the lifespan, significant medical morbidity, high rates of self-harm, economic and social burden and frequent treatment resistance with residual symptoms between major episodes. At present, there is no empirical foundation to support any assumption about the long-term course or outcome of bipolar illness when it arises in childhood or adolescence, or the effects of conventional pharmacotherapies in altering its course and limiting potentially adverse outcomes. The proposed research articulates specific descriptive aims that draw on adult findings and outlines core methodological requirements for such an endeavor.
Conclusions: Innovations in the description and quantitative analysis of prospective longitudinal clinical data must now be extended to large, systematically ascertained pediatric cohorts recruited through multicenter studies if there is to be a meaningful scientific advance in our knowledge of the enduring effects of bipolar illness and the potential value of contemporary approaches to its management.